John French, MD
Ophthalmology · Southern Pines, NCNPI 1366649345
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,315 of the $5,447 with a category attached, or 60.9%. 20 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 40.5% of the total. Reporting peaked in 2019 at $2,786 and has fallen 71.8% since, to $787 in 2025.
Across 137 payments — averaging $39.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$1K
- Biotissue Holdings Inc.$572
- Glaukos Corporation$347
- Dompe US, Inc.$265
- Bausch & Lomb Americas Inc.$169
- plus $582 from 14 others
Across 7 payments — averaging $566.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$4K
What the payments were for
- Consulting fees$2,13239%
- Food & beverage$3,31561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 2 | $2,205 |
| Alcon | 51 | $1,306 |
| Biotissue Holdings Inc. | 37 | $572 |
| Glaukos Corporation | 14 | $347 |
| Dompe US, Inc. | 10 | $265 |
| Bausch & Lomb Americas Inc. | 3 | $169 |
| Kala Pharmaceuticals, Inc. | 3 | $160 |
| Rxsight Inc | 1 | $75 |
| Rayner Intraocular Lenses Limited | 4 | $68 |
| Shire North American Group Inc | 2 | $47 |
| AbbVie | 1 | $42 |
| Carl Zeiss Meditec, Inc. | 1 | $31 |
| Tarsus Pharmaceuticals, Inc. | 1 | $28 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Novartis | 1 | $22 |
| Amgen | 1 | $20 |
| MML US, Inc. | 1 | $15 |
| Ivantis, Inc | 1 | $14 |
| Omeros Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Symfony IOL$2,132
- MIEBO$125
- XIIDRA$125
- INVELTYS$124
How this compares
$5,447 in reported general payments places this provider in the 80th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 950 | $36,286 |
| RestasisCyclosporine | 30 | $30,727 |
| JardianceEmpagliflozin | 14 | $8,106 |
| Fluorometholone | 60 | $5,931 |
| Loteprednol Etabonate | 23 | $5,056 |
| Ofloxacin | 425 | $4,609 |
| ValacyclovirValacyclovir Hcl | 86 | $4,353 |
| MoxifloxacinMoxifloxacin Hcl | 63 | $1,436 |
| Latanoprost | 56 | $584 |
| Timolol Maleate | 18 | $410 |
| Ketorolac Tromethamine | 19 | $387 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 42 | $320 |
| Dorzolamide Hcl | 13 | $262 |
| Brimonidine Tartrate | 30 | $240 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $42 | $30,72730 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $23 | $5,05623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Southern Pines
- Arghavan AlmonySouthern Pines$87K
- Anna FakadejSouthern Pines$18K
- Winston GarrisSouthern Pines$10K
- Robert SharpeSouthern Pines$8K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.